DeepBio Scientific offers an AI co‑scientist platform that uses the first equivariant foundation model for mRNA design, delivering higher expression prediction accuracy and a four‑fold improvement in Frechet BioDistance.
Funding
Funding not disclosed
Founders
Product
Problem
Designing effective mRNA therapeutics is time‑consuming, costly, and relies heavily on expert intuition, leading to low success rates and long development timelines. Existing computational tools often lack accuracy and the ability to optimize multiple objectives such as expression, stability, safety, and manufacturability simultaneously.
Solution
DeepBio Scientific provides an AI co‑scientist platform built on the first equivariant foundation model for mRNA design (Equi‑mRNA). The Helixir AI Platform lets researchers and biotech teams self‑serve mRNA sequence design with AI‑guided codon optimization, stability prediction, and expression scoring, delivering roughly 10 % higher expression prediction accuracy and a four‑fold improvement in generative fidelity. For pharmaceutical partners, DeepBio offers custom design programs that combine the platform’s world‑model architecture with dedicated support and milestone‑based royalty structures. By reasoning across biological systems rather than simple pattern matching, the platform accelerates candidate optimization, reducing development time by 30‑50 % and improving overall success rates.
Target Audience
Primary users are academic researchers, biotech teams, and pharmaceutical companies developing mRNA therapeutics who need rapid, high‑accuracy sequence design and optimization.
Features
- Equivariant foundation model (Equi‑mRNA) with SO(2) symmetry encoding for accurate codon selection
- Multi‑objective optimization of expression, stability, safety, and manufacturability
- AI‑driven stability and degradation profile predictions validated on six biological datasets
- Generative sequence engine delivering 4.3× higher fidelity mRNA constructs than baseline models
- Proven performance metrics: ~10 % better expression prediction and ~4× Frechet BioDistance improvement
- Self‑serve Helixir AI Platform with free starter access and pay‑as‑you‑go pricing
- Custom pharma partnership programs with dedicated support, milestone‑based pricing, and royalty upside